Christopher R. Cline - Sep 1, 2022 Form 3 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Financial Officer
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Sep 1, 2022
Transactions value $
$0
Form type
3
Date filed
9/1/2022, 06:19 PM
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TVTX Common Stock 28.7K Sep 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 40K $12.51 Direct F1
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 15K $32.49 Direct F1
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 20K $16.23 Direct F1
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 20K $17.44 Direct F1
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 12.5K $25.25 Direct F1
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 10K $17.96 Direct F2
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 12.5K $15.46 Direct F3
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 16.3K $26.88 Direct F4
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 17.5K $27.50 Direct F5
holding TVTX Employee Stock Option (Right to Buy) Sep 1, 2022 Common Stock 5K $28.55 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
F3 One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 One-fourth of the shares subject to the stock option vested and became exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F5 One-fourth of the shares subject to the stock option will vest and become exercisable on January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F6 One-fourth of the shares subject to the stock option will vest and become exercisable on April 10, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.